DOCSLIB.ORG

RESI SF Program Guide 1-05-2016

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

JANUARY 12, 2016 RESI SAN FRANCISCO, CA Early stage investors, fundraising CEOs, scientist-entrepreneurs, strategic partners, and service providers now have an opportunity to Make a Compelling Connection ONSITE GUIDE LIFE SCIENCE NATION Connecting Products, Services & Capital #RESISF2016 | RESIConference.com | January 12, 2016 | Marine's Memorial Club & Hotel 10th floor: Panels, Exhibition elevators & resi innovation challenge Exhibiting resi companies innovators Track 1 - Commandant’s room - BIOTECH 1 2 3 4 5 INVESTOR 1 2 3 4 5 6 7 PANELS 8 17 - regimental room - 21 22 23 24 25 6 18 19 20 21 19 9 20 16 22 23 24 25 7 MEDTECH Track 2 Track 18 30 29 28 27 26 INVESTOR 15 PANELS 17 16 15 14 13 12 11 10 14 13 12 11 10 9 8 13 - Heritage room - 11th floor: partnering forum, Workshops breakfast buffet, LUNCH, Cocktail reception elevators PARTNERING Forum - Crystal Ballroom - Reception WORKSHOPS - Library Room - Food & Beverage - Crystal Lounge - elevators 12th floor: LUNCH 12:00 -1:00 pm - bar - - Service Area - - Leatherneck Steakhouse - Quick guide to each floor 12 PM - 1 PM Lunch (200 Seats) FLOOR 7 AM - 8 AM Breakfast Buffet 8 AM - 5 PM Partnering Forum 8 AM - 5 PM Workshops FLOOR 10 AM - 5 PM Registration 12 PM - 1 PM Lunch (350 Seats) 5 PM - 7 PM Cocktail Reception Sponsored by: Investor Panels 8 AM - 5 PM Exhibition Hall FLOOR RESI Innovation Challenge Registration 7 AM - 10 AM FLOOR (Please register on the 11th floor after 10 AM) content Welcome from Dennis Ford - - - - - - - 2 RESI Schedule - - - - - - - - - - - - - - - - - 3 RESI Innovation Challenge - - - - - - - 4 Exhibiting Companies - - - - - - - - - - 13 Investor Panels - - - - - - - - - - - - - - - 18 Early Stage Workshops - - - - - - - - - 37 Partnering Forum - - - - - - - - - - - - - - 40 Sponsors - - - - - - - - - - - - - - - - - - - - 41 Media Partners - - - - - - - - - - - - - - - 43 General Information - - - - - - - - - - - 44 Notes - - - - - - - - - - - - - - - - - - - - - - 47 1 welcome from dennis ford Life Science Nation (LSN) is thrilled to be back at the annual healthcare conference week for our second RESI San Francisco event. It's the largest RESI conference yet, with over 700 registered attendees, including over 300 early stage global investors! We're delighted that RESI has garnered this enthusiastic audience during a very busy week for the life science industry. We've expanded the bandwidth of RESI Partnering in order to offer more opportunities for RESI attendees to connect with each other face-to-face. By using the RESI Partnering system to nd fellow attendees based on t, you can nd meeting partners who align with your focus. With that match as a basis, RESI is a venue for compelling conversations between startups and investors in the life science space. LSN would like to extend our thanks to the speakers who are participating in RESI's two Investor Panel tracks, and the presenters of the RESI Workshops. We're very glad that you're here to share your expertise with the entrepreneurs and investors who attend RESI. We’d also like to bring your attention to the RESI Innovation Challenge. The RESI Innovators are showcasing cutting-edge life science technologies in poster displays throughout the exhibit hall. Inside your RESI badge you’ll nd ve tokens of RESI Cash you can use to “invest” in the most promising of these technologies. Take the time to invest your RESI Cash wisely, and join us at the evening reception as we announce the winners! Thank you for joining us and making this the biggest RESI yet. We're excited to be here for the rst stop on RESI's 2016 tour. We hope to see you later this year in Houston, Toronto, and Boston. Until then, enjoy the show! Sincerely, Dennis Ford Founder & CEO, Life Science Nation LIFE SCIENCE NATION Connecting Products, Services & Capital 2 resi schedule Track 1: Track 2: Track 3: Track 4: Investor Investor Early Stage Partnering Panels Panels Entrepreneur Forum Workshops - regimental room - - Heritage room - - Library Room - - Crystal Ballroom - 7:00 - 8:00 AM: Registration & Breakfast (Crystal Lounge) LIFE SCIENCE NATION 8:00 Connecting Products, Services & Capital - BIOTECH MEDTECH 8:50 Angels angels fundraising AM boot camp 9:00 Corporate VCs Diagnostic MORNING - & Strategic Non-Dilutive 9:50 investors EARLY STAGE AM Investment Funding PARTNERING 10:00 FORUM - big medtech Realities of translating 10:50 pharma strategics med-tech innovation AM into commercial success 11:00 EARLY STAGE medical device - THERAPEUTICS Crowdfunding 11:50 investors AM INVESTORS & Reg A+ 12:00 - 1:00 PM: Break for Lunch (Crystal Lounge & Leatherneck Steakhouse) 1:00 - venture CONSUMER 1:50 philanthropy HEALTH How to Value PM Your Startup 2:00 Due to the popularity of - BIOTECH medtech AFTERNOON Sessions, there is no 2:50 family offices family offices workshop scheduled to run EARLY STAGE PM during this time slot. PARTNERING 3:00 orphan & rare FORUM tales from - disease boston 3:50 the road PM investors innovation capital LIFE SCIENCE NATION 4:00 asia-pacific healthcare it Connecting Products, Services & Capital - branding & 4:50 investors investors PM messaging 5:00 - 7:00 PM: Cocktail Reception (Crystal(Crystal Ball Lounge)room & Crystal Lounge) 3 resi innovation challenge - Commandant’s room - 10th floor RESI $ Innovation 100,000 Challenge RESI CASH www.RESIConference.com We welcome you to participate in the RESI Innovation Challenge! The RESI Innovation Challenge is a virtual investment contest, and the investor is you! As you explore the exhibit hall, you will encounter 30 RESI Innovators showcasing their technology via poster displays. Along with your RESI attendee badge, you will nd ve RESI Cash tokens that you can use to 'invest' in the most promising RESI Innovators. Take a look around this collection of cutting-edge life science technology, and leave your RESI Cash with the entrepreneurs that most inspire you. The invested capital will be tallied up and the top three winners will be awarded during the cocktail reception at the end of the day. Winners will be featured in the Life Science Nation (LSN) newsletter with readership of 20,000. • FirstLSN Prize: Investor Complimentary Platform for tickets a year. to 3 RESI Conference Series events of your choice (2 tickets per event) • Second Prize: Complimentary tickets to 2 RESI Conference Series events of your choice (2 tickets per event) • Third Prize: Complimentary tickets to 1 RESI Conference Series event of your choice (2 tickets) 4 resi innovation challenge - Commandant’s room - 10th floor RESI Innovators Easel 1 Easel 2 Easel 3 Easel 4 Easel 5 Easel 6 Easel 7 Easel 8 Easel 9 Easel 10 Easel 11 Easel 12 Easel 13 Easel 14 Easel 15 Easel 16 Easel 17 Easel 18 Easel 19 Easel 20 Easel 21 Easel 22 Easel 23 Easel 24 Easel 25 Easel 26 Easel 27 Easel 28 Easel 29 Easel 30 5 resi innovators Easel 1 - 8 Vicus Therapeutics is a clinical-stage immuno-oncology company developing neuro-immune-modulators (“NIMs”) as combination therapies for pancreatic and other solid cancers. Our lead NIM asset, VT-122, is a chrono-formulation of etodolac and propranolol. VT-122 modulates beta adrenergic, peptidergic and prostaglandin signaling cascades to damp tumor promoting inammation and restore immune surveillance. Unlike other immune modulators, VT-122 also improves treatment tolerance. Proof-of-concept has been demonstrated in one Phase 2 and two cohort studies of advanced pancreatic and liver cancers. In 2016, VT-122 will be evaluated as a combination therapeutic in a Phase 2/3 clinical trial for metastatic pancreatic cancer, an indication for which VT-122 was granted an Orphan Drug designation, and as a neo-adjuvant/adjuvant therapeutic in a Phase 2 clinical trial for ovarian cancer. The surgeon’s lack of tactile feedback during minimally invasive laparoscopic and robotic surgery leads to difculty in safely visualizing and manipulating blood vessels, ureters, and bile ducts. Briteseed combats this problem by building smart surgical tools using low-cost optical technology to non-invasively visualize both between and near the jaws of a surgical tool in real time. This combination hardware and software solution is exible enough to be seamlessly integrated into a spectrum of surgical tools. These smart tools will provide imaging and diagnostic capabilities without interrupting surgical workow, increasing user adoption. By raising the quality and decreasing overall cost of care, Briteseed provides value to surgeons and the hospital administrations that support them. NuvOx Pharma is developing a platform of drugs that increase the blood's oxygen carrying capacity and decrease tissue hypoxia. The company has pre-clinical data showing improved outcomes in oncology, sickle cell crisis, stroke, and several other life-threatening indications. A Phase 1b clinical trial is in progress for the rst indication, oncology. A Series A-2 round is currently open. Immunophotonics is developing inCVAX, an in situ autologous cancer vaccine that uses whole tumor cells as the source of antigens from individual patients without ex-vivo preparations. inCVAX utilizes a two injection procedure into one or more tumors: The rst injection is an optical ber (coupled to a laser) that heats a portion of the tumor to induce immunogenic cell death and tumor antigen release. The second injection is our experimental drug, a proprietary synthesized carbohydrate polymer, intended to activate antigen-presenting cells, potentially triggering a systemic anti-tumor immune response. During a rst-in-human clinical trial, several patients experienced shrinkage of local tumors and distant metastases with a favorable safety prole – in some cases this led to a complete response. Accel Diagnostics is developing novel point-of care, smartphone-enabled, diagnostic products addressing the medical need of rapid and accurate diagnostic and monitoring solutions for the growing chronic patients – in primary cares and homes. AccelDx’s proprietary technology, pScreen™, enables doctors and patients to perform lab-quality biomarker blood-based diagnostic tests anytime, anywhere. pScreen™ is transforming the diagnostics paradigm, by bringing signicant advantages in terms of simplicity, time to result, care delivery, and cost.
Recommended publications
  • Annual Report

    Annual Report

    Building Long-term Wealth by Investing in Private Companies Annual Report and Accounts 12 Months to 31 January 2021 Our Purpose HarbourVest Global Private Equity (“HVPE” or the “Company”) exists to provide easy access to a diversified global portfolio of high-quality private companies by investing in HarbourVest-managed funds, through which we help support innovation and growth in a responsible manner, creating value for all our stakeholders. Investment Objective The Company’s investment objective is to generate superior shareholder returns through long-term capital appreciation by investing primarily in a diversified portfolio of private markets investments. Our Purpose in Detail Focus and Approach Investment Manager Investment into private companies requires Our Investment Manager, HarbourVest Partners,1 experience, skill, and expertise. Our focus is on is an experienced and trusted global private building a comprehensive global portfolio of the markets asset manager. HVPE, through its highest-quality investments, in a proactive yet investments in HarbourVest funds, helps to measured way, with the strength of our balance support innovation and growth in the global sheet underpinning everything we do. economy whilst seeking to promote improvement in environmental, social, Our multi-layered investment approach creates and governance (“ESG”) standards. diversification, helping to spread risk, and is fundamental to our aim of creating a portfolio that no individual investor can replicate. The Result Company Overview We connect the everyday investor with a broad HarbourVest Global Private Equity is a Guernsey base of private markets experts. The result is incorporated, London listed, FTSE 250 Investment a distinct single access point to HarbourVest Company with assets of $2.9 billion and a market Partners, and a prudently managed global private capitalisation of £1.5 billion as at 31 January 2021 companies portfolio designed to navigate (tickers: HVPE (£)/HVPD ($)).
  • Mbamission's Insider's Guide

    Mbamission's Insider's Guide

    mbaMission’s Insider’s Guide The Wharton School University of Philadelphia Philadelphia, PA 2019–2020 presented by Applying to Business School? mbaMission is your partner in the process! Our team of dedicated, full-time admissions experts has helped thousands of applicants get into their dream MBA programs. These skilled storytellers and MBA graduates will work one-on-one with you to help you discover, select, and articulate your unique stories and stand out from the crowd. Why mbaMission? 15+ years of experience advising Ranked number one firm by GMAT tens of thousands of business Club and Poets&Quants school applicants Exclusively recommended by Extensive, unparalleled library of Services available for all stages of Manhattan Prep since 2009 supplementary content the application process Schedule a free, 30-minute consultation at www.mbamission.com/consult, and start getting answers to all your MBA admissions questions! +1-646-485-8844 [email protected] www.mbamission.com About mbaMission With our collaborative, full-time team of experienced advisors, mbaMission has elevated and professionalized the world of MBA admissions consulting, earning the exclusive recommendation of the world’s leading GMAT prep firms, Manhattan Prep and Kaplan GMAT, and hundreds more verified five-star reviews on GMAT Club than any other such firm. mbaMission prides itself on its high-touch client engagement model and robust library of free content that includes these Insider’s Guides as well as our Complete Start-to-Finish MBA Admissions Guide. Having already helped thousands of aspiring MBAs from around the world gain entry into elite US and international business schools, mbaMission continues to grow and improve in our quest to “graduate” additional classes of satisfied clients.
  • The Prospectus

    The Prospectus

    THE PROSPECTUS Join the conversation @firstrockcap Dated the 5th day of December 2019 A copy of this Prospectus was delivered to the Registrar of Companies for registration pursuant to Section 372 of the Companies Act of Jamaica, 2004 (as amended) and was so registered on December 18th 2019. The Registrar of Companies accepts no responsibility whatsoever for the contents of this Prospectus. A copy of this Prospectus was also delivered to the Financial Services Commission for registration pursuant to section 26 of the Securities Act and was so registered on December 19th 2019. The Financial Services Commission has not approved the offer of Shares for which subscription is invited nor has the Commission passed upon the accuracy or adequacy of this Prospectus. Initial Public Offer by First Rock Capital Holdings Limited of up to 106,083,332 Shares of the Company in two (2) classes: (i) 51,053,333 US$ Class A Ordinary Shares at USD Subscription Price of US$0.12 or the US$ Reserved Share Price of US$0.108 per Share; and (ii) 55,029,999 J$ Class B Ordinary Shares at the J$ Subscription Price which is the J$ equivalent of US$0.12 per Share (calculated using the Subscription Rate as defined herein) or the J$ Reserved Share Price which is the J$ equivalent of US$0.108 per Share (calculated using the Subscription Rate as defined herein). with the right to upsize the offer by an additional 53,041,666 Shares in the event of oversubscription. Registered Address Financial & Corporate Services Ltd 1st Floor, Bourbon House, Bourbon Street, Castries, Saint Lucia Local Address Suite 6, 14 Canberra Crescent, Kingston 6, Saint Andrew Telephone (876) 774-1733 Email [email protected] Website www.firstrockcap.com FIRST ROCK CAPITAL HOLDINGS | PROSPECTUS 3 Initial Public Offer of up to 106,083,332 Shares of the Company in two (2) classes: 1.
  • Executive Branch Personnel Public Financial Disclosure Report (OGE Form 278E)

    Executive Branch Personnel Public Financial Disclosure Report (OGE Form 278E)

    Nominee Report | U.S. Office of Government Ethics; 5 C.F.R. part 2634 | Form Approved: OMB No. (3209-0001) (March 2014) Executive Branch Personnel Public Financial Disclosure Report (OGE Form 278e) Filer's Information Gottlieb, Scott Commissioner of Food and Drugs, Department of Health & Human Services Other Federal Government Positions Held During the Preceding 12 Months: None Names of Congressional Committees Considering Nomination: ● Committee on Health, Education, Labor, and Pensions Electronic Signature - I certify that the statements I have made in this form are true, complete and correct to the best of my knowledge. /s/ Gottlieb, Scott [electronically signed on 03/17/2017 by Gottlieb, Scott in Integrity.gov] Agency Ethics Official's Opinion - On the basis of information contained in this report, I conclude that the filer is in compliance with applicable laws and regulations (subject to any comments below). /s/ Fischmann, Elizabeth, Certifying Official [electronically signed on 03/28/2017 by Fischmann, Elizabeth in Integrity.gov] Other review conducted by /s/ Hall, Randall, Ethics Official [electronically signed on 03/28/2017 by Hall, Randall in Integrity.gov] U.S. Office of Government Ethics Certification /s/ Shaub, Walter M, Certifying Official [electronically signed on 03/28/2017 by Shaub, Walter M in Integrity.gov] 1. Filer's Positions Held Outside United States Government # ORGANIZATION NAME CITY, STATE ORGANIZATION POSITION HELD FROM TO TYPE 1 American Enterprise Institute Washington, DC, Non-Profit Resident Fellow 2/2007 Present District of Columbia 2 New Enterprise Associates See Endnote Chevy Chase, Corporation Venture Partner 9/2007 Present Maryland 3 New York University School of Medicine See Endnote New York, New University/Colle Clinical 1/2011 Present York ge Assistant Professor 4 T.R.
  • Private Placement Activity Chris Hastings | Chastings@Signalhill.Com | 917-621-3750 8/7/2017 – 8/11/2017 (Transactions in Excess of $15 Million) Commentary

    Private Placement Activity Chris Hastings | [email protected] | 917-621-3750 8/7/2017 – 8/11/2017 (Transactions in Excess of $15 Million) Commentary

    Private Placement Activity Chris Hastings | [email protected] | 917-621-3750 8/7/2017 – 8/11/2017 (Transactions in excess of $15 million) Commentary . Iconectiv, a developer of telecommunications software and interconnection technology, raised $200 million — Francisco Partners led the deal. Information Resources, a provider of consulting and advisory services, raised $100 million. Investors include New Mountain Capital and Silver Canyon Group. Appboy, a developer of a life-cycle engagement platform, raised $50 million in Series D funding at a $350 million pre-money valuation — ICONIQ Capital led the round. Oryx Vision, a developer of next-generation automotive LiDAR technology, raised $50 million in Series B funding — Third Point Ventures and WRV led the round. Chef’d, a provider of an online food sales and delivery service, raised $35 million in Series B funding. Amplitude, a provider of a mobile and web-based analytics platform, raised $30 million in Series C funding — IVP led the round. Signals Analytics, a developer of an insights as a service augmented intelligence platform, raised $25 million in Series C funding — Pitango Venture Capital led the round. InContext Solutions, a developer of 3D virtual simulation technology, raised $22 million in Series F funding — Beringea and Intel Capital led the round. Stratford School, a provider of academic programs, raised $21 million. Investors include Warburg Pincus. Guideline, a provider of automated investment technology, raised $15 million in Series B funding at a $70 million pre-money valuation — Felicis Ventures led the round. Company Company Amount Date Investors Series Company Description / Comments Name Location Raised ($M) Information Technology Developer of telecommunications software and interconnection technology.
  • Private Equity Performance Investment Horizon Performance Through March 31, 2006

    Private Equity Performance Investment Horizon Performance Through March 31, 2006

    LOS ANGELES CITY EMPLOYEES' RETIREMENT SYSTEM JUNE 30, 2006 ALTERNATIVE INVESTMENT REVIEW GSB BUILDING ONE BELMONT AVENUE, 9TH FLOOR BALA CYNWYD, PA 19004 TELEPHONE: (610) 934-2222 FAX: (610) 617-9855 WWW.HAMILTONLANE.COM TABLE OF CONTENTS SECTION 1: PORTFOLIO UPDATE SECTION 2: PORTFOLIO ASSESSMENT Performance Summary By Investment......................................................................................... 2-1-2-3 Performance Summary By Category............................................................................................ 2-4 Private Equity Benchmarks.......................................................................................................... 2-5-2-6 SECTION 3: PORTFOLIO ANALYTICS Commitments By Vintage Year.................................................................................................... 3-1 Portfolio Strategic Diversification as Measured by Reported Market Value................................. 3-2 Portfolio Strategic Diversification as Measured by Total Exposure.............................................. 3-3 Underlying Investment Diversification By Industry Classification................................................. 3-4 Cost and Fair Market Value (Exposed Market Value) of Portfolio Holdings................................. 3-5 Underlying Investment Diversification By Geographic Location................................................... 3-6 Public vs. Private Holdings..........................................................................................................
  • Environmental Services Insider Mergers & Acquisitions Overall M&A Activity

    Environmental Services Insider Mergers & Acquisitions Overall M&A Activity

    Environmental Services Services Insider Insider Volume II, No II July 2011 Highlights The BGL Environmental Services M&A Activity Insider is published by Inside: Brown Gibbons Lang & Company, a leading independent investment bank • Th e middle market is active, with M&A volume in the fi rst half BGL Spotlight: serving middle market companies and of 2011 up 33 percent over the same period a year ago. Q2 ’11 their owners throughout the U.S. and deal fl ow was up 34 percent over the prior quarter and 41 percent internationally. over the comparable period last year. Valuations remain strong in a Private Equity Roundtable Page 6 competitive deal market, with the median strategic buyer multiple Private equity fi rms discuss sector exceeding a healthy 8x EBITDA. Th e median fi nancial buyer opportunities, M&A, and the state of the Brown Gibbons multiple also remains healthy, equaling 7.4x EBITDA for middle fi nancing markets. market transaction values below $500 million (Page 2). Lang & Oil Collections & Re-Refi ning Page 18 • M&A activity in environmental services is following the same Company positive trend, with deal fl ow in the fi rst half up 31 percent from Market Update the year ago period. Sectors leading transaction activity are Solid The industry continues to undergo change as Cleveland Waste, up nearly two-fold and Metals Recycling & E-Waste, competition for the waste material heats up, 1111 Superior Avenue doubling over the same period. Q2 ’11 deal fl ow slowed from the and participants are encouraged by Valvoline’s Suite 900 prior quarter with Solid Waste and Metals Recycling & E-Waste entry into the market.
  • Buyer Brochure

    Buyer Brochure

    BB UU YY EE RR BB RR OO CC HH UU RR EE Valufinder Group, Inc. 95 Horatio Street Suite 301 New York, NY 10014 USA Telephone: 212-243-1133 Fax: 212-243-1838 Email: [email protected] http://www.valufindergroup.com Copyright © Valufinder Group, Inc. 2004. All Rights Reserved. ABOUT VALUFINDER 1 At A Glance 2 Our Team 3 - 4 Referrals 5 - 7 Careers 8 FOR BUYERS 9 Problems Buyers Face 10 - 11 The Valufinder Solution 12 Valufinders Methodology 13 - 14 Data Accumulation 15 - 16 Matching Buyers & Sellers 17 - 18 Completing Transactions 19 – 20 Retained Searches 21 The Valufinder Difference 22 Initial Stage 23 Candidate Identification 24 Candidate Contact 25 - 27 Additional Information 28 - 29 Partial Client List 30 NEWS & TRANSACTIONS 31 Select Transactions 32 - 36 Case Studies 37 Private Sellers 38 - 43 Corporate Divestitures 44 - 49 Add-on Acquisitions 50 - 55 Company News 56 - 59 CONTACT US 60 Copyright © Valufinder Group, Inc. 2004. All Rights Reserved. For over a quarter century, buyers and owners in the middle market have relied on Valufinder's experience and acumen to reach the goal of a fair and equitable transaction. At Valufinder, we take the time to understand the objectives of the owner and the acquisition criteria of the buyer, in order to provide realistic and appropriate opportunities, while striving to give honest, intelligent and objective advice. Valufinder is clearly the most talented and prolific deal initiator I've worked with in my career. Valufinder Group is distinctive because of their intelligence and creativity in developing proprietary ideas. They are tireess. I can't think of anyone better at origination than Valufinder.
  • Silicon Valley London Woodside Capital Partners (WCP)

    Silicon Valley London Woodside Capital Partners (WCP)

    Silicon Valley London Woodside Capital Partners (WCP) proudly releases the inaugural healthcare report “State of Digital Health”. In 2016, healthcare cost in the US was $3.3 Trillion – 17.9% of GDP, passing $10,000 per capita mark for the first time ever. According to CMS, by 2026, the figure is projected to grow to $5.7 Trillion – 19.8% of GDP. The answer to curbing and reversing the trend with respect to healthcare costs lies in large part to the movement towards Digital Health, or ‘Health Tech’. The proliferation of devices and applications across the healthcare spectrum has led to a data tsunami – the “what”. Machine Learning, Artificial Intelligence and overall Big Data analytics are leading to real-time actionable insights – the “so what”. We have entered the realm of the Internet of Medical Things (IoMT), with ubiquitous connectivity and measurement of everything from our vitals and nutrition to physical activity and medical compliance. We are just starting to leverage that data in a meaningful way and seeing early impact on health and well-being. In 2017, venture investments in Digital Health startups exceeded $6 Billion for the first time, and the trend seems to be accelerating with $1.6 Billion invested in Q1, 2018. The juxtaposition of rising healthcare costs and increased Digital Health investments is not all that surprising. Advances in underlying real-time analytics and potential of leading edge innovations around genomics are turning the perceived fiction of personalized medicine into a real possibility. Foundational disruptions such as Blockchain, while relatively nascent, are creating excitement (and some anxiety) around secure, immutable data sharing across silos – with healthcare as the ideal use case.
  • Proposal for CLA Innovation and Entrepreneurship

    Proposal for CLA Innovation and Entrepreneurship

    REVISED DRAFT Proposal for Innovation and Entrepreneurship Minors Empowering People for a Better Society Texas A&M University Spring Semester 2016 Please provide comments to Patricia Thornton, professor of sociology and entrepreneurship, [email protected] I thank the task force members on an innovation and entrepreneurship minor in the College of Liberal Arts, Keven Barge, Steve Puller, Charles Samuelson, and Leroy Dorsey, and Dean Pam Matthews, Associate Deans Steven Oberhelman and John Hurtado, Dr. Richard Lester of the Center for New Venture Entrepreneurship, Magda Lagoudas, sand Drs. William Brown, Timothy Gronberg, William Clark, David Vaught, Irene Moyna, Maura Ives, Jane Sell, and the members of College of Liberal Arts Department Heads Meeting for their helpful comments in shaping these ideas 1 Introduction The university serves as the catalyst for transforming knowledge to service in society and the economy. The origins of this transformation stem from extending the study of Liberals Arts to practical subjects such as agriculture, architecture, military science, engineering, and science. In Europe, this legacy created the natural sciences during the renaissance. In the U.S., it ignited the Morrill Acts of 1862 and 1890 to establish land grant colleges focusing on industrial and agricultural innovation to service social class mobility in the aftermath of the industrial revolution. More recently, the 1980 Bayh-Dole Act ushered in the life science and information technology revolution, allowing university, small business, and non-profit ownership of innovation from federally funded research. These transformations have led to a spectacular expansion of the university as the cornerstone of the new knowledge society. In this proposal we make the argument for building on this rich heritage of interdisciplinary inclusiveness in knowledge production in service to society and the economy through a campus-wide interdisciplinary effort to unite research, teaching, and practice of innovation and entrepreneurship.
  • Missouri PE Deal Report 1H 2019

    Missouri PE Deal Report 1H 2019

    Missouri PE Deal Report 2H 2019 This report provides an overview of private equity activity in the state of Missouri. Our report offers key market place trends and drivers as well as professional, high-level insights on the quantity, type, region, and industry of deals reported in the 2H of 2019 in Missouri. R.L. Hulett & Company uses data from Pitchbook for all accompanying charts. For more information please contact Trevor Hulett at [email protected]. 2020 Outlook Missouri PE Deal Report Coronavirus Impact S&P 500 Index vs. WTI Crude Oil As of this writing, the S&P 500 Index had dropped 19% from its all- S&P 500 WTI Crude Oil time high set in Feb 2020 amid fears over the coronavirus outbreak 3600 70.00 coupled with a correction in the oil and gas market. 65.00 3400 Volatility has been extremely high in the equity markets in recent 60.00 3200 55.00 weeks, which could present challenges in dealmaking and could put 3000 50.00 pressure on transaction volumes over the next 3-6 months. 45.00 2800 According to PitchBook, the global M&A market is already set for its 40.00 2600 slowest first two months since 2006. 35.00 2400 30.00 In the state of Missouri, we expect deal volume in the first half of 2020 to see a similar decline. Trade War & Tariffs Global Deal Count in Jan & Feb Under the so-called "phase one" trade deal signed in January, China 8400 pledged to boost US imports by $200bn above 2017 levels and 7400 strengthen intellectual property rules.

  • Private Equity & Venture Capital

    VOLUME 14, ISSUE 2 ■ FEBRUARY 2018 PRIVATE EQUITY & VENTURE CAPITAL SPOTLIGHT PRIVATE EQUITY FUNDRAISING IN IN THIS ISSUE 2017: A GLOBAL STORY In 2017, 921 private equity funds reached a fi nal close, securing just over $453bn, the largest amount of capital FEATURE 3 raised in any year. In this feature we examine the private equity industry’s year of success. Private Equity Fundraising in 2017: A Global Story Find out more on page 3 FEATURE 8 First-Time Fund Managers INDUSTRY NEWS 11 FIRST-TIME FUND MANAGERS First-time private equity fund managers secured $26bn THE FACTS in capital commitments across 226 funds in 2017. ■ Consistent 13 We examine fundraising and performance trends for Performing Fund fi rst-time funds as well as investor appetite for these vehicles. Managers ■ Largest Fund 15 Find out more on page 8 Managers ■ Largest Investors 16 ■ Performance Benchmarks 18 CONFERENCES 19 JUST RELEASED: 2018 PREQIN GLOBAL PRIVATE EQUITY & VENTURE CAPITAL 2018 PREQIN GLOBAL PRIVATE EQUITY REPORT & VENTURE CAPITAL REPORT Order Your Copy Download Sample Pages ISBN: 978-1-912116-05-8 $175 / £125 / €150 www.preqin.com All data in this newsletter can be downloaded to Excel for free Sign up to Spotlight, our free monthly newsletter, providing insights into Alt Credit Intelligence European and US Fund Services Awards: Best Data and Information performance, investors, deals and Provider | Africa Global Funds Awards 2016: Best Research and Data Provider | The Queen’s fundraising, powered by Preqin data: Award for Enterprise: International Trade | HedgeWeek Global Awards: Best Global Hedge Fund Research Provider | CAIA Corporate Recognition Award SIGN UP www.preqin.com/contact| [email protected] REALISE THE POTENTIAL OF PRIVATE EQUITY IN CHINA 7 - 9 May 2018 The Four Seasons Hotel, Beijing www.superreturnchina.com Dear Spotlight reader, We are very pleased to off er a 10% discount to Spotlight readers for registrations to SuperReturn China in Beijing on 7 – 9 May 2018.